NCT06761417View on ClinicalTrials.gov

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

February 1, 2028

Conditions
Solid TumorsChildrenAdolescents
Interventions
DRUG

Mitoxantrone liposome

Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.

DRUG

Capecitabine

Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.

DRUG

Anlotinib

Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.

Trial Locations (1)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER